Get the Stockscreener App
36.38
3.50%
-1.32
After Hours:
36.45
0.07
+0.19%
Gsk Plc Adr stock is traded at $36.38, with a volume of 7.08M.
It is down -3.50% in the last 24 hours and up +7.13% over the past month.
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, antiviral, and vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
See More
Previous Close:
$37.70
Open:
$37.52
24h Volume:
7.08M
Relative Volume:
1.33
Market Cap:
$74.25B
Revenue:
$39.71B
Net Income/Loss:
$3.17B
P/E Ratio:
23.65
EPS:
1.5382
Net Cash Flow:
$6.05B
1W Performance:
+2.88%
1M Performance:
+7.13%
6M Performance:
-5.95%
1Y Performance:
-12.86%
1-Day Range:
$36.37
$37.61
1-Week Range:
$34.22
$37.91
52-Week Range:
$31.71
$45.92
Gsk Plc Adr Stock (GSK) Company Profile
Name
Gsk Plc Adr
Sector
Industry
Phone
-
Address
-
Compare GSK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GSK
Gsk Plc Adr
|
36.38 | 74.25B | 39.71B | 3.17B | 6.05B | 1.5382 |
|
LLY
Lilly Eli Co
|
870.37 | 827.20B | 40.86B | 8.37B | -2.28B | 9.25 |
|
NVO
Novo Nordisk Adr
|
87.17 | 386.95B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
JNJ
Johnson Johnson
|
153.51 | 344.63B | 88.82B | 14.07B | 19.03B | 5.79 |
|
ABBV
Abbvie Inc
|
192.97 | 341.01B | 56.33B | 4.28B | 15.62B | 2.40 |
|
MRK
Merck Co Inc
|
88.05 | 251.88B | 64.17B | 17.12B | 14.84B | 6.7297 |
Gsk Plc Adr Stock (GSK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-15-24 | Downgrade | Deutsche Bank | Buy → Hold |
| Nov-12-24 | Downgrade | Jefferies | Buy → Hold |
| Oct-31-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-08-24 | Downgrade | UBS | Buy → Neutral |
| May-30-24 | Initiated | Goldman | Neutral |
| Mar-04-24 | Upgrade | Guggenheim | Neutral → Buy |
| Feb-13-24 | Upgrade | Citigroup | Neutral → Buy |
| Jan-23-24 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-16-24 | Resumed | UBS | Buy |
| Jan-03-24 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Mar-17-23 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-27-23 | Resumed | Goldman | Buy |
| Jan-03-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-11-22 | Downgrade | UBS | Neutral → Sell |
| Sep-15-22 | Upgrade | Credit Suisse | Underperform → Neutral |
| Sep-08-22 | Downgrade | Jefferies | Buy → Hold |
| Aug-05-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jul-21-22 | Resumed | Citigroup | Neutral |
| Feb-11-22 | Downgrade | DZ Bank | Buy → Hold |
| Nov-05-21 | Upgrade | Barclays | Underweight → Equal Weight |
| Jun-24-21 | Upgrade | Deutsche Bank | Sell → Hold |
| Mar-23-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-04-21 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-20-21 | Downgrade | Credit Suisse | Neutral → Underperform |
| Jan-15-21 | Initiated | Deutsche Bank | Hold |
| Nov-02-20 | Upgrade | Liberum | Hold → Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Feb-12-20 | Downgrade | Shore Capital | Hold → Sell |
| Jan-16-20 | Downgrade | Barclays | Equal Weight → Underweight |
| Dec-02-19 | Initiated | SVB Leerink | Outperform |
| Nov-21-19 | Upgrade | UBS | Neutral → Buy |
| Oct-11-19 | Upgrade | Cantor Fitzgerald | Hold → Buy |
| Sep-03-19 | Resumed | Citigroup | Neutral |
| Sep-03-19 | Upgrade | Societe Generale | Sell → Buy |
| Aug-13-19 | Resumed | JP Morgan | Neutral |
| Jun-17-19 | Resumed | Morgan Stanley | Underweight |
| Mar-08-19 | Downgrade | Shore Capital | Buy → Hold |
| Feb-22-19 | Downgrade | UBS | Buy → Neutral |
| Jan-14-19 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| Dec-11-18 | Resumed | Jefferies | Buy |
| Oct-09-18 | Initiated | Guggenheim | Neutral |
| Aug-30-18 | Downgrade | Liberum | Buy → Hold |
| Apr-04-18 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Mar-22-18 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-09-18 | Upgrade | Kepler | Reduce → Hold |
View All
Gsk Plc Adr Stock (GSK) Latest News
GSK PLC Stockholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against GSK - GlobeNewswire Inc.
O’Reilly Automotive, Inc [ORLY] stock for 2,179,380 USD was sold by CONN TAMARA F. - Knox Daily
Buying Buzz: GSK Plc ADR [GSK] 10% Owner GSK plc purchases 2,791,930 shares of the company - Knox Daily
Bear Of The Day: GSK PLC (GSK) - Yahoo Finance
MNKD Shares Experience Surge in Value - Knox Daily
Torrid Holdings Inc [CURV] Shares Jump Approximately 29.38% Over the Year - Knox Daily
D-Wave Quantum Inc [QBTS] Records 200-Day SMA of $2.33 - Knox Daily
Rumble Inc [RUM] Records 50-Day SMA of $10.53 - Knox Daily
Investor Alert: Robbins LLP Informs Stockholders of the GSK PLC Class Action - PR Newswire
Rosen Law Firm Urges GSK plc (NYSE: GSK) Investors with Large Losses to Contact the Firm for Information About Their Rights - Business Wire
Wall Street Analyst Downgrade Melco Resorts & Entertainment Ltd ADR [MLCO]. What else is Wall St. saying - The DBT News
GSK Beats on Q4 Earnings & Sales, Stock Up on Raised Long-Term Outlook - Yahoo Finance
For Juniper Networks Inc [JNPR], Analyst sees a rise to $40. What next? - The DBT News
Market Analysts see Apollo Global Management Inc [APO] gaining to $188. Time to buy? - The DBT News
Tuya Inc ADR [TUYA] Revenue clocked in at $280.97 million, up 66.48% YTD: What’s Next? - The DBT News
GSK Plc ADR (GSK) Stock: A Comprehensive 52-Week Review - The InvestChronicle
The Significance of Moving Averages in BridgeBio Pharma Inc Inc. (BBIO) Price Performance - The InvestChronicle
Top investors say GSK Plc ADR (GSK) ticks everything they need - SETE News
GSK share price - GSK
Earnings Preview: GSK (GSK) Q4 Earnings Expected to Decline - Yahoo Finance
Are Investors Keen On Selling Holdings In GSK Plc ADR (NYSE: GSK)? - Stocks Register
Dow Inc (NYSE: DOW) Is A Buzzing Hot Stock - Stocks Register
The 10 Best Companies to Invest in Now - Morningstar
In 2025, GSK Plc ADR (NYSE: GSK) Shares Will Likely Be Bullish - Stocks Register
18 of the Best Stocks and ETFs to Buy Based on 2025 Expert Forecasts - Morningstar
Precidian Investments Builds Out Its ADRhedged ETF Lineup with Four New Strategies, Offering Targeted International Exposure with Integrated Currency Hedge - Business Wire
Gsk Plc ADR (GSK-N) QuotePress Release - The Globe and Mail
Best International Companies to Own: 2025 Edition - Morningstar
FDA Accepts GSK's Filing for Expanded Use of Nucala in COPD - MSN
GSK Stock Declines 20% In 3 Months: Should You Buy, Sell Or Hold? - Barchart
GSK Stock Declines 20% in 3 Months: Should You Buy, Sell or Hold? - Zacks Investment Research
FDA Accepts GSK's Filing For Expanded Use Of Nucala In COPD - Barchart
GSK Expands Vaccine Collaboration With Zhifei in China - MSN
GSK Follows Rivals, to Cap Out-of-Pocket Inhaler Cost in US - MSN
GSK Gets EC Nod for Liquid Version of Meningococcal Vaccine Menveo - Zacks Investment Research
10 Best Value Stocks to Buy for the Long Term - Morningstar
5 Stocks to Buy While They’re Still Cheap After Earnings - Morningstar
Diabetes Care Nutrition Market Report 2024 with Forecasts to 2029 - GlobeNewswire Inc.
Weekly Upgrades and Downgrades - InvestorPlace
The Best Defensive Stocks to Buy - Morningstar
GSK Plc ADR (NYSE: GSK) Has Outstanding Potential - Stocks Register
Gsk Plc Adr Stock (GSK) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):